C

CureVac

739 employees

CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
cancer therapies
mRNA therapeutics
Therapeutics
manufacturing
research and development
molecular therapies
Biopharma
prophylactic vaccines
oncology

Date founded

2000

Funding rounds raised

Total raised

$338M

from 8 investors over 8 rounds

C

CureVac raised $300M on September 15, 2020

Investors: Federal Ministry of Education and Research, Germany

C

CureVac raised $126M on July 21, 2020

Investors: Qatar Investment Authority

C

CureVac raised $85M on July 6, 2020

Investors: European Investment Bank

C

CureVac raised $338M on June 15, 2020

Investors: KfW

C

CureVac raised $108M on November 3, 2015

Investors: Bill & Melinda Gates Foundation, Baillie Gifford and Sigma Group

C

CureVac raised $76M on March 5, 2015

Investors: Bill & Melinda Gates Foundation

FAQ